The role of anti-tumor necrosis factor-α therapy in pyoderma gangrenosum associated with inflammatory bowel disease

American Journal of Clinical Dermatology

Volumn 8, Issue 2, 2007, Pages 67-77

  Reguiaï, Ziad ^a   Grange, Florent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPERGILLOSIS; BACTERIAL PNEUMONIA; BIOLOGICAL THERAPY; BRONCHITIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EDEMA; ENTERITIS; FACE EDEMA; HAND EDEMA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEPATITIS B; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIP DISEASE; LIVER DISEASE; LIVER FAILURE; LUPUS LIKE SYNDROME; LYMPHOMA; MENINGITIS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYALGIA; MYCOBACTERIOSIS; NEUROLOGIC DISEASE; NONHUMAN; OPTIC NEURITIS; PATHOGENESIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PYODERMA GANGRENOSUM; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; STAPHYLOCOCCUS INFECTION; SUNBURN; T LYMPHOCYTE; THORAX PAIN; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VIRUS PNEUMONIA; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; PYODERMA GANGRENOSUM; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250665552     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708020-00002     Document Type: Review

References (83)

1. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Derm Syphilol 1930; 22: 655-80
2. Powell F, Su D, O'Perry H. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34 (3): 395-409
3. Callen JP. Pyoderma gangrenosum. Lancet 1998; 351 (9102): 581-5
4. Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143 (4): 728-32
5. Chow R, Ho V. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34 (6): 1047-60
6. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53 (2): 273-83
7. Wollina U. Clinical management of pyoderma gangrenosum: clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002; 3 (3): 149-58
8. Campbell S, Cripps S, Jewell DP. Therapy insight: pyoderma gangrenosum - old disease, new management. Nat Clin Pract Gastroenterol Hepatol 2005; 2 (12): 587-94
9. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21 (3): 251-8
10. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52-65
11. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323-33
12. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC-II trial. Gut. Epub 2007 Feb 13
13. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55 (4): 598-606
14. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121 (5): 1088-94
15. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003; 23 (3): 76-85
16. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7 (3): 251-9
17. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353 (9151): 459-61
18. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94 (1): 174-81
19. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor-alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339 (8785): 89-91
20. Murch SH, Lamkin VA, Savage MO, et al. Location of tumour necrosis factor-alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34 (12): 1705-9
21. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347 (6): 417-29
22. Van Dullemen H, Meenan J, Stronhorst A, et al. Mediators of mucosal inflammation: implications for therapy. Scand J Gastroenterol Suppl 1997; 223: 92-8
23. Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115 (3): 250-9
24. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130 (7): 2060-73
25. ten Hove T, van Montfrans C, Peppelenbosch MP. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50 (2): 206-11
26. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15 (4): 463-73
27. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337 (15): 1029-35
28. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease: seven years on. Aliment Pharmacol Ther 2006; 23 (4): 451-63
29. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl. 5: V1-16
30. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl. 1: i16-35
31. Holtmann M, Neurath M. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005; 20 (1): 1-8
32. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9): 876-85
33. Present DH. Crohn's fistula: current concepts in management. Gastroenterology 2003; 124 (6): 1629-35
34. Van den Bosch JM, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356 (9244): 1821-2
35. Hughes A, Jackson J, Callen J. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284 (12): 1546-8
36. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55 (4): 505-9
37. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn's disease: effects of TNF-α blockade with infliximab. Scand J Gastroenerol 2002; 37 (9): 1108-10
38. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98 (8): 1821-6
39. Tan M, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001; 137 (7): 930-3
40. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002; 205 (3): 278-80
41. Mimouni D, Anhalt GJ, Kouba DJ, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148 (4): 813-6
42. Zaccagna A, Bertone A, Puiatti P, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol 2003; 13 (3): 258-60
43. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 2004; 49 (9): 1454-7
44. Rispo A, Scarpa R, Di Girolamo E. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005; 34 (5): 387-91
45. Kouklakis G, Moschos J, Leintiadis GI, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease: a case report. Rom J Gastroenterol 2005; 14 (4): 401-3
46. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 2006; 54 (3): S128-33
47. Stichweh D, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005; 22 (3): 262-5
48. McGowan J, Johnson C, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004; 3 (4): 441-3
49. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005; 16 (5-6): 345-9
50. Hubbard V, Friedmann A, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005; 152 (5): 1059-61
51. Fonder M, Cummins D, Ehst B, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5: e8
52. Van den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124 (7): 1774-85
53. Sieper J, Van den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005; 34 Suppl. 1: 23-7
54. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 2005; 153 (3): 689-91
55. Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 2005; 30 (2): 134-6
56. Jenne L, Sauter B, Thumann P, et al. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol 2004; 150 (2): 380-2
57. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission: case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79 (1): 37-46
58. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494): 1367-74
59. Hanauer SB, Feagan FG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541-9
60. Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006; 9 (3): 221-33
61. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96 (3): 722-9
62. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65 (15): 2179-208
63. Colombel J, Loftus E Jr, Tremaine V, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126 (1): 19-31
64. Baert F, Noman M, Vermeire S. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348 (7): 601-8
65. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98 (6): 1315-24
66. Maini R, St Clair EW, Breedvelt F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354 (9194): 1932-9
67. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098-104
68. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162 (6): 3504-11
69. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344 (14): 1099-100
70. Nakelchik M, Mangino JE. Reactiviation of histoplasmosis after treatment with infliximab. Am J Med 2002; 112 (1): 78
71. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19 (6): 320-34
72. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4 (3): 153-61
73. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116 (5): 305-11
74. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138 (10): 807-11
75. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled pilot trial on infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-40
76. Maini R, Breedveld F, Kalden J, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50 (4): 1051-65
77. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64 (2): 229-34
78. Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006; 31 (3): 460-1
79. Le Bureau du Ministre de la Santé et des Solidarités (French Ministry of Health home page) [online]. Available from URL: http://www.sante.gouv.fr [Accessed 2007 Apr 3]
80. Bodger K. Economic implications of biological therapies for Crohn's disease. Pharmacoeconomics 2005; 23 (9): 875-88
81. Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of it use in rheumatoid arthritis. Pharmacoeconomics 2004; 22: 107-32
82. Colombel JF, Rutgeerts P, Yan S, et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients [abstract]. Gastroenterology 2002; 122 Suppl. 1: A613
83. O'Donnell B, Powell FC. Cyclosporine treatment of pyoderma gangrenosum. J Am Acad Dermatol 1991; 24 (1): 141-3